Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes - Trial SLCTR_2012_004
Access comprehensive clinical trial information for SLCTR_2012_004 through Pure Global AI's free database. This Phase 3 trial is sponsored by Boehringer Ingelheim India (Pvt) Ltd and is currently Completed. The study focuses on Diabetes Mellitus, Type 2.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2012_004
Phase 3
Completed
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2012_004
Linaglitpin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
A 24-week, Randomized, Double-blind, Active-controlled, Parallel Group Trial to Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotherapy in Newly Diagnosed, Treatment-naïve, Uncontrolled Type 2 Diabetes Mellitus Patient
Study Focus
Interventional
Sponsor & Location
Boehringer Ingelheim India (Pvt) Ltd
Canada, Estonia, Guatemala, India, Israel, Malaysia, Mexico, Philippines, Poland, Russia, Slovakia,
Timeline & Enrollment
Phase 3
May 23, 2012
N/A
ICD-10 Classifications
Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2012_004
Non-Device Trial